{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-021501","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.372877+00:00","generated_at":"2026-05-17T23:11:26.594046+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata Therapeutics to effect 1-for-10 reverse stock split effective August 1, 2025","bullets":["Reverse stock split at 1:10 ratio effective 12:01 a.m. ET on August 1, 2025.","Every ten outstanding common shares convert to one share; no fractional shares (cash in lieu).","CUSIP changes to 249845504; trading on Nasdaq on split-adjusted basis expected August 1.","Board authorized split ratio range of 1:2 to 1:30 at July 15 annual meeting; Board selected 1:10.","Outstanding stock options and warrants will be adjusted proportionally."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-021501","json":"https://secwatch.observer/filing/0001641172-25-021501.json","markdown":"https://secwatch.observer/filing/0001641172-25-021501.md","text":"https://secwatch.observer/filing/0001641172-25-021501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225021501/0001641172-25-021501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225021501/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:11:26.594046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75c24b0e790f99e672c8a6620d875ad846b3cccd","claim":"Dermata Therapeutics, Inc.: Certificate of Amendment filed to effect a one-for-10 reverse stock split of common stock (effective 2025-08-01).","evidence_excerpt":"On July 30, 2025, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on August 1, 2025, a one-for-10 (1:10) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225021501/0001641172-25-021501-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-01"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}